Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changesHAMILTON, Raymond F; PARSLEY, Ed; HOLIAN, Andrij et al.American journal of physiology. Lung cellular and molecular physiology. 2004, Vol 30, Num 6, pp L1202-L1209, issn 1040-0605Article

Cyclophosphamide versus placebo in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.The New England journal of medicine. 2006, Vol 354, Num 25, pp 2655-2666, issn 0028-4793, 12 p.Article

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.American journal of respiratory and critical care medicine. 2007, Vol 176, Num 10, pp 1026-1034, issn 1073-449X, 9 p.Article

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease : Results from the scleroderma lung studyKHANNA, Dinesh; XIAOHONG YAN; RILEY, David J et al.Arthritis and rheumatism. 2007, Vol 56, Num 5, pp 1676-1684, issn 0004-3591, 9 p.Article